$ABVX $CDTX $RVMD $SLS Why am I sharing this with my fellow Sellas Brothers and Sisters? Because shorts try to create a doubt in your heads and “Doubt kills more dreams everyday than failure ever will” Hold with Conviction and stay strong 💪 ✌️🙏❤️🩹
$ABVX $CDTX $RVMD $SLS A picture is worth a thousand words $CDTX was my biggest hit of all time. I started buying $CDTX a little over $2.13 after watching the ticker passing by on CNBC a few years ago.👇 Merck completed its acquisition of Cidara Therapeutics (NASDAQ: CDTX) on January 7, 2026, buying the biotechnology company for $221.50 per share in cash. The total transaction value was approximately $9.2 billion. Hold with Conviction because opportunities like this come very rarely. Don’t step over a hundred dollar 💵 Bills to pick up Pennie’s.👇 ✌️🙏❤️🩹
$SLS Correct! Plus these numbers don’t include July/August 2026 buys. I have been saying for months now. We will see Tutes at over 80% after BO.
Same exact pattern at $CDTX $RVMD $ABVX
Before they hit triple digits. CURATIVE GPS Data+ Smart money buying hand over fist right before BO.
✌️🙏❤️🩹
$SLS $CDTX $RVMD $ABVX I saw the same filings at $CDTX $RVMD $ABVX before their massive jump to triple digits. Smart money is accumulating at an incredible pace. ✌️🙏❤️🩹
$ABVX $CDTX $RVMD $SLS RVMD MC jumped by $17 Billion dollars in first 3 hours of trading after positive Phase 3 RASolute 302 trial data for its oral RAS(ON) inhibitor daraxonrasib in second-line metastatic pancreatic cancer (PDAC). The drug met all primary and key secondary endpoints, roughly doubling median overall survival and reducing the risk of death by 60% compared to standard chemotherapy. Not remotely close to a CURE but once again any positive results in deadly cancers go long way for very sick patients. ✌️🙏❤️🩹
$SLS Part 2. Sellas PPS will be halted multiple times in coming days. Volume will be over 200 Million shares on the day of GPS Regal Pivotal Registrational CURATIVE Phase 3 Data. SLS PPS will be halted multiple times that day and close over $120.00+ I have been part of $CDTX $RVMD $ABVX run ups but SLS is in a league if it’s own with CURATIVE data in one of the deadliest cancer on the planet. Market over corrects both ways, I don’t think lot of people are mentally prepared about what coming here will be one of the most violent upticks in the History of Wall Street because GPS will be only CURATIVE cancer platforms with 0 Toxicity, 0 Adverse event, mild side effect of Injection site small bump, Excellent QOL. I am mentally prepared for an uptick from $120- $180 after 1st trading halt. ✌️🙏❤️🩹
$SLS Giada, As I have noticed with my other Buy out plays like for Ex: $CDTX Institutional Ownership jumped to 76% before BO.
Before the buyout of Cidara Therapeutics (CDTX) by Merck, institutional investors held approximately 77% to 78% of the company's outstanding shares.
In 2025, Cidara Therapeutics Inc. (NASDAQ: CDTX) recorded an extraordinary year highlighted by a 721.76% stock price surge driven by its pending $9.2 billion acquisition by Merck.Key Stock & Performance Stats2025 Performance: The stock skyrocketed by 721.76% over the calendar year.Acquisition Price: Merck agreed to acquire CDTX at $221.50 per share in cash.
✌️🙏❤️🩹
$CRDF I made almost 20x last year on $CDTX that was a Company in similar situation. The were going to develop a new product to treat influenza but before they did a 20:1 R/S. Everyone yielling. It depends on what comes afterwards. Cidara was acquired by Merck for 9.2 bililion. Before R/S company value was about 50 million.
$SLS Part 3. Longs Have you ever seen a Nasdaq Listed late Stage Biotech Company not lined up for a single big medical conference?
Sellas has over $150 Million cash on hand right now.
Not even a single presentation in over 2 months.
Last Investor presentation slides on the website is from February 2026.
I saw the same exact actions from $CDTX Cidara Therapeutics (NASDAQ:CDTX) was acquired by Merck for $9.2 billion in an all-cash transaction. Merck paid $221.50 per share, and the acquisition closed in early January 2026.
$CDTX final 10k post BO showed 6 suitors that went back and forth for over 6 months before the final deal was consummated and accepted by BO.
Remember SLS doesn’t have to file any 8k until deal is accepted by BOD. Sellas independent BOD not a single open market purchase after Nov. 2025 Big JP Morgan 1x1 attended by Dr. Stergiou and CMO Cicic. Negotiations have been going on back and forth since late Nov. 2025 PPS has jumped 10 times since that. Coincidence? 😉 ✌️🙏❤️🩹
@SellasgpsCurativeBAT11 Ohhh the money I made on $CDTX after being down sooo sooo much... I'd love to see that kinda buyout here. AND I'm up on $SLS so so much... 🤑
$SLS Baker Brothers filing was the craziest one. They never owned a single share of $CDTX but I don’t know how they squeezed in last minute. Baker Bros. Advisors completely liquidated and sold off their entire position in Cidara Therapeutics (CDTX).
This final exit occurred during the early 2026 reporting period, several months after Merck announced its definitive agreement to acquire Cidara for $221.50 per share. The hedge fund officially parted ways with its 227,272 remaining shares, capitalizing on the stock's massive surge after Merck's acquisition deal. By the end of Q1, Cidara was dropped from their 13F portfolio entirely.
🤷 ✌️🙏❤️🩹
@SmartCapitall I understand what you’re saying but $CDTX was at those low levels during 2022, it’s now 2026, according to the chart it took them until 2026 to reach the $200 levels, that’s a 4yr timeline, do you think $SLS could take years to reach the $200 mark or do you feel it’s something that’ll happen sooner than that? Only asking as I’m curious
$SLS Think about this, where did the rumor come from, who leaked the BO talks to the media? It was Merck in the case of $CDTX! They quietly leaked so the SP of CDTX could climb up to around $100 from $20 so their BO @$220 wouldn’t seem too ridiculous for the Merck shareholders. Same thing is happening to Sellas! BPs want $SLS to go up to at least $50 before announcing the BO @$100+ just to get their own shareholders’ approval.
